Signal MD Anderson phase 1 trial reported disease stabilization in pancreatic cancer

Summary

The report cites an early clinical result for engineered exosomes in one of the hardest cancers to treat. In a phase 1 trial at the University of Texas MD Anderson Cancer Center, the participants were pancreatic cancer patients who had run out of other treatment options. Engineered exosomes were used to target a mutation that had resisted every previous drug. Patients in the trial showed stabilization of their disease. The report presents this as one of several early studies testing what exosome delivery can achieve, not as proof of a finished therapy. The outlook stresses that no exosome-based therapy had FDA approval as of late 2025.